Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | FABP3 | P05413 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cridanimod SCHEMBL3801665 | 1.00 | GLA (1.00) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL3372087 | 1.00 | GLA (1.00) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL27895128 | 0.98 | GLA (0.96) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL3375823 | 0.98 | GLA (0.96) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL3375819 | 0.98 | GLA (0.96) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| SCHEMBL15732891 | 0.93 | GLA (0.87) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| SCHEMBL29859932 | 0.90 | KDM4E (1.00) | GLAKDM4EAPEX1ALDH1A1POLB | |
| SCHEMBL150053 | 0.90 | KDM4E (1.00) | GLAKDM4EAPEX1ALDH1A1POLB | |
| SCHEMBL21027234 | 0.86 | GLA (0.74) | GLAKDM4EAPEX1P2RX4POLB | |
| SCHEMBL21027012 | 0.86 | GLA (0.74) | GLAKDM4EAPEX1P2RX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986465-B1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX PLANCK GESELLSCHAFT (DE) | 2026-05-13 | — | — | EP | claimed |
| EP-4713029-A1 | MODIFIED CELL, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING A MODIFIED CELL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V. (DE) | 2026-03-25 | — | — | EP | claimed |
| EP-4713340-A2 | COMPOSITIONS AND METHODS FOR PEPTIDE-BASED MODULATORS OF HUMAN PAPILLOMAVIRUS ONCOPROTEIN E6 | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| US-20250327249-A1 | A PRINTABLE OR PRINTED PAPER FOR DECORATIVE ELEMENTS, DECORATIVE ELEMENTS COMPRISING A PRINTED PAPER AND A METHOD FOR MANUFACTURING SAID DECORATIVE ELEMENT | UNILIN, BV (BE) | 2025-10-23 | — | — | US | claimed |
| US-20250188143-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| US-20250186623-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| EP-4303360-B1 | A PRINTABLE OR PRINTED PAPER FOR DECORATIVE ELEMENTS, DECORATIVE ELEMENTS COMPRISING A PRINTED PAPER AND A METHOD FOR MANUFACTURING SAID DECORATIVE ELEMENT | UNILIN BV (BE) | 2025-06-04 | — | — | EP | claimed |
| EP-4489794-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | Fundación para la Investigación Médica Aplicada (ES) | 2025-01-15 | — | — | EP | claimed |
| EP-4489795-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | Fundación para la Investigación Médica Aplicada (ES) | 2025-01-15 | — | — | EP | claimed |
| WO-2022223619-A1 | COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY | INSTITUT CURIE (FR) | 2022-10-27 | — | — | WO | claimed |
| US-20220324893-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-10-13 | — | — | US | claimed |
| US-20220306670-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-09-29 | — | — | US | claimed |
| CN-114874731-A | Perovskite photovoltaic packaging material, device and preparation method thereof | 长春工业大学 | 2022-08-09 | — | — | CN | claimed |
| WO-2022157613-A1 | THERMOSETTING RESIN COMPOSITION FOR LAMINATE PANEL, METHOD FOR MANUFACTURING A PANEL WITH A THERMOSETTING RESIN COMPOSITION AND A LAMINATE PANEL COMPRISING A THERMOSETTING RESIN | FLOORING INDUSTRIES LIMITED, SARL (LU) | 2022-07-28 | — | — | WO | claimed |
| WO-2022139613-A1 | BLOOD AND URINE-BASED TEST FOR PREDICTION OF PROGRESSION OF DIABETIC KIDNEY DISEASE | QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT (QA) | 2022-06-30 | — | — | WO | claimed |
| EP-3986466-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. (DE) | 2022-04-27 | — | — | EP | claimed |
| EP-3986465-A1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. (DE) | 2022-04-27 | — | — | EP | claimed |
| EP-3962493-A2 | METHODS OF MODULATING IMMUNE ACTIVITY/LEVEL OF IRF OR STING OR OF TREATING CANCER, COMPRISING THE ADMINISTRATION OF A STING MODULATOR AND/OR PURINERGIC RECEPTOR MODULATOR OR POSTCELLULAR SIGNALING FACTOR | Flagship Pioneering Innovations V, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| US-20220031825-A1 | IMMUNOLOGICAL ADJUVANT AND VACCINE COMPOSITION INCLUDING STING AGONIST | QURATIS INC (KR) | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | PGRMC2, PGRMC1, PGR | GLA 4405/4885KDM4E 603/4885APEX1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.